Isolation and Characterization of Clinical Triazole Resistance Aspergillus fumigatus in Iran
,
Abstract
Background: Aspergillus fumigatus is a major cause of allergic syndromes, aspergilloma and life-threatening invasive infections in immunocompromised hosts. To date, a wide range of mutations in A. fumigatushave been described conferring azole-resistance, which commonly involves modifications in the cyp51A-gene (substitutions at codons G54, G138, P216, F219, M220, G448 and specifically codon L98 in combination with a 34-bp tandem repeat in the promoter region of the gene), the target for azole antifungals. We investigated the prevalence of azole-resistance in clinical A. fumigatus isolates obtained from patients in Iran during 2010 to 2014.
Methods: Overall, 172clinical A. fumigatus isolates obtained from patients with underlying disease including transplantation, granulocytopenia, chronic liver disease, chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Samples were collected between Jan 2009 and Nov 2014 from five provinces of Iran (Tehran, Shiraz, Isfahan, Khorasan razavi and East Azerbaijan). Antifungal susceptibility test was determined according to EUCAST reference method for itraconazole (ITC), voriconazole (VRC) and posaconazole (POS). All isolates were confirmed by amplification of the partial tubulin gene.
Results: Of 172 A. fumigatus isolates tested, six isolates (3.5%) had high MIC values of ITC (>16 mg/L) and VRC (≥4 mg/L). All six isolates showed a multi-resistant phenotype with high MICs of ITC and VRC.
Conclusion: We determined in-vitro susceptibility a profile of 172 clinically isolates of A. fumigatus against triazole in Iran. Azole-resistance is an emerging problem in A. fumigatus and international surveillance is warranted.
Zaoutis TE, Heydon K, Chu JH et al (2006). Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics, 117:e711-e716.
Denning DW (1998). Invasive aspergillosis. Clin Infect Dis, 26(4):781-803.
Howard SJ, Pasqualotto AC, Denning DW (2010). Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect, 16:683-688.
Snelders E, Melchers WJ, Verweij PE (2011). Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol, 6:335-347.
Mohammadi F, Hashemi SJ, Zoll J et al (2016). Quantitative analysis of single-nucleotide polymorphism for rapid detection of TR34/L98H-and TR46/Y121F/T289A-positive Aspergillus fumigatus isolates obtained from patients in Iran from 2010 to 2014. Antimicrob Agents Chemother, 60:387-392.
Verweij PE, Ananda-Rajah M, Andes D et al (2015). International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat, 21-22:30-40.
Steinmann J, Hamprecht A, Vehreschild MJ et al (2015). Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother, 70:1522-6.
Mohammadi F, Dehghan P, Nekoeian SH, Hashemi SJ (2016). Determination of an-tifungal susceptibility patterns among the environmental isolates of Aspergillus fu-migatus in Iran. Adv Biomed Res, 5:136.
Odds FC, Brown AJ, Gow NA (2003). Antifungal agents: mechanisms of action. Trends Microbiol, 11:272-279.
Howard SJ, Cerar D, Anderson MJ et al (2009). Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis, 15:1068.
Verweij PE, Snelders E, Kema GH et al (2009). Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis, 9:789-795.
Mann PA, Parmegiani RM, Wei S-Q et al (2003). Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob Agents Chemother, 47:577-581.
Mellado E, Diaz-Guerra T, Cuenca-Estrella M, Rodriguez-Tudela J (2001). Identification of two different 14-α sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol, 39:2431-2438.
Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al (2007). A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother, 51:1897-1904.
Espinel-Ingroff A (2001). Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol, 39:1360-1367.
Cuenca‐Estrella M, Arendrup MC, Chryssanthou E et al (2007). Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST‐EUCAST). Clin Microbiol Infect, 13:1018-1022.
Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A et al (2008). Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother, 52:1244-1251.
Balajee SA, Borman AM, Brandt ME et al (2009). Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol, 47:877-884.
Camps SM, van der Linden JW, Li Y et al (2012). Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother, 56(1):10-6.
Testing SoASTotEECfAS (2008). EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds. Clin Microbiol Infect, 14:982-984.
Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat, 16:81-95.
Seyedmousavi S, Hashemi SJ, Zibafar E et al (2013). Azole-resistant Aspergillus fumigatus, Iran. Emerg Infect Dis, 19:832-4.
Warris A (2015). Azole-resistant aspergillosis. J Infect, 71 Suppl 1:S121-5.
Howard SJ, Webster I, Moore CB et al (2006). Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents, 28:450-453.
Bueid A, Howard SJ, Moore CB et al (2010). Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother, 65:2116-2118.
Burgel PR, Baixench MT, Amsellem M et al(2012). High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother, 56:869-874.
Snelders E, Van Der Lee HA, Kuijpers J et al (2008). Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med, 5:e219.
Verweij PE, Mellado E, Melchers WJ (2007). Multiple-triazole–resistant aspergillosis. N Engl J Med, 356:1481-1483.
Anderson JB (2005). Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol, 3:547-556.
Lockhart SR, Frade JP, Etienne KA et al (2011). Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother, 55:4465-8.
Snelders E, Rijs AJ, Kema GH et al (2009). Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol, 75:4053-4057.
Gomez-Lopez A, Garcia-Effron G, Mellado E et al (2003). In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother, 47:3085-3088.
Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al (2004). Substitutions at methionine 220 in the 14α-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother, 48:2747-2750.
Nascimento AM, Goldman GH, Park S et al (2003). Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother, 47:1719-1726.
Xiao L, Madison V, Chau AS et al (2004). Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother, 48:568-574.
Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E et al (2008). Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother, 52:2468-2472.
van Leer-Buter C, Takes RP, Hebeda KM et al (2007). Aspergillosis—and a misleading sensitivity result. The Lancet, 370:102.
| Files | ||
| Issue | Vol 47 No 7 (2018) | |
| Section | Original Article(s) | |
| Keywords | ||
| Azole resistance Aspergillus fumigatus Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
